Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Les Sulewski
TRU
Les Sulewski
Truist Financial
Wall Street Analyst
★★★☆☆
#1774
on 13Foresight · ranked by our own returns
30%
Success Rate
-3.6%
Average Return
3 of 10 calls profitable · -8.8% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 30% of Les Sulewski's ratings turned a profit when each position was held for 1 year — averaging -3.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

65 Buy 13 Hold 0 Sell
Les's Stock Coverage 14 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CRMD
Cormedix
 May 15, 2026 BUY Strong Buy
+73.5% avg upside
13 analysts
 — +13.1%
COLL
Collegium Pharmaceutical
 May 14, 2026 BUY Strong Buy
+25.7% avg upside
8 analysts
 — -3.0%
ANIP
ANI Pharmaceuticals
 May 11, 2026 HOLD Strong Buy
+28.6% avg upside
11 analysts
 — ·
VTRS
Viatris
 May 08, 2026 BUY Buy
+48.2% avg upside
21 analysts
$20.00
30.03% Upside
 -7.8%
VNDA
Vanda
 May 07, 2026 BUY Strong Buy
+253.1% avg upside
13 analysts
$18.00
210.42% Upside
 -1.7%
PCRX
Pacira Pharmaceuticals
 May 01, 2026 BUY Buy
+74.3% avg upside
21 analysts
 — -5.9%
TSE:BHC
Bausch Health Companies
 May 01, 2026 HOLD Buy
+783.6% avg upside
29 analysts
 — ·
TEVA
Teva Pharmaceutical
 Apr 30, 2026 BUY Buy
-6.8% avg upside
39 analysts
$45.00
42.96% Upside
 -7.2%
AMRX
Amneal Pharmaceuticals
 Apr 23, 2026 BUY Strong Buy
+5.6% avg upside
18 analysts
 — +27.1%
BTMD
biote
 Apr 16, 2026 BUY Strong Buy
+109.5% avg upside
8 analysts
$4.00
76.91% Upside
 -6.2%
FR:MEDCL
MedinCell SA
 May 27, 2025 BUY Strong Buy
+23.3% avg upside
3 analysts
$22.00
10.15% Downside
 ·
CVS
CVS Health
 Aug 08, 2024 BUY Strong Buy
+3.1% avg upside
38 analysts
 — +18.5%
TSE:DHT.UN
DRI Healthcare
 Jul 26, 2024 BUY Strong Buy
+10.7% avg upside
5 analysts
$19.60
10.25% Upside
 ·
XAIR
Beyond Air
 Jul 09, 2024 HOLD Strong Buy
+5809.0% avg upside
10 analysts
 — -62.8%
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Les Sulewski — Frequently Asked Questions
How accurate are Les Sulewski's stock ratings?
Based on the calls 13Foresight could measure, about 30% of Les's ratings were profitable over a one-year hold, with an average return of -3.6% per rating, or -8.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Les ranked on 13Foresight?
Les Sulewski is currently ranked #1774 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Les cover?
Les most recently has ratings on CRMD, COLL, ANIP, VTRS, VNDA, PCRX, TSE:BHC, TEVA, AMRX, BTMD, FR:MEDCL, CVS and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.